Clinical trials: Male Pattern Baldness
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)
The purpose of the the study is to evaluate the ability of injections of Ji Gami(TM) C to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451151
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 2 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Androgenetic Alopecia
Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia
This is a randomized, open-label phase 1/2a study designed to evaluate the pharmacokinetics, pharmacodynamics, and safety of AD-303A (topical formulation) and AD-3031 in male patients with androgenetic alopecia.
- Trial name
- NCT07490327
- Testing
- AD-303A, AD-3031
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Moogene Medi Co., Ltd
AGA
A Phase 3 Clinical Study Patients With Androgenetic Alopecia (AGA)
A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Clinical Study ,the mean change from baseline in vertex target area hair count (TAHC) after treatment for 24 weeks.
- Trial name
- NCT05135468
- Testing
- CU-40102 Spray
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
Male Pattern Hair Loss
Safety and Efficacy of HST 001 in Male Pattern Hair Loss
HST 001 (also known as hair stimulating complex [HSC]) is a mixture of growth factors secreted by human dermal fibroblasts when cultured in proprietary bioreactors which are then harvested and concentrated to specific ranges.
- Trial name
- NCT04435847
- Testing
- HST 001, Phosphate Buffered Saline
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Histogen
Androgenetic Alopecia
A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss
The primary purpose of the study is to evaluate the efficacy of a topical 5% minoxidil formulation in males for the treatment of pattern hair loss.
- Trial name
- NCT00151515
- Testing
- minoxidil
- Where
- 15 sites in United States
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Alopecia
A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia
The aim of this Phase III study is to compare the efficacy, safety and tolerability of dutasteride (0.5mg) with placebo for 6 months, in Korean male subjects with androgenetic alopecia in the vertex region, types IIIv, IV and V…
- Trial name
- NCT00441116
- Testing
- Dutasteride 0.5mg oral tablets
- Volunteers
- 153 people
- Sponsor
- GlaxoSmithKline
Androgenetic Alopecia
Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia
This study will evaluate the skin pharmacokinetics and tolerability of bimatoprost Formulation A and Formulation B following 14 days of once daily topical administration in male participants with androgenetic alopecia (AGA).
- Trial name
- NCT02848300
- Testing
- Bimatoprost 1% Formulation A, Bimatoprost 1% Formulation B
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Allergan
Androgenetic Alopecia
Benefits of a Cosmetic Anti-hair Loss in Males With Hair Loss
Androgenetic alopecia (AGA), also known as androgenic alopecia or male pattern baldness, is the most common type of progressive hair loss.
- Trial name
- NCT06590779
- Testing
- Aminexil® active+ lotion, Finasteride 1mg
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Male Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA)
Phase I Clinical Trial of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia
This study is testing CG2001, a new medicine that is applied as a light foam to the scalp and is being developed to treat male-pattern hair loss (androgenetic alopecia). The main goals are to find out: 1.
- Trial name
- NCT07038941
- Testing
- CG2001
- Where
- China
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Beijing Dayspring Pharmaceutical Technology Co., Ltd
Androgenetic Alopecia, Pattern Baldness
Evaluation of the Niostem Headset for Hair Growth and Hair Quality
This double-blind, randomized, placebo-controlled clinical trial evaluates the Niostem headset, an electronic device designed to support hair growth, reduce hair loss, and improve hair quality.
- Trial name
- NCT06994819
- Testing
- niostem headset (Active)
- Where
- Germany
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Mane Biotech GmbH
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899)
Evaluate the ability of injections of Ji Gami(TM) and Ji Gami(TM) DO to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451112
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Androgenetic Alopecia
Phase III Study of KX-826 With Adult Male Patients With AGA
This is a phase III, multi-center, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of KX-826 for topical use in Chinese adult male patients with androgenetic alopecia (AGA).
- Trial name
- NCT06126965
- Testing
- KX-826-（5%） BID
- Where
- 26 sites in China
- Volunteers
- 740 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Androgenetic Alopecia
To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period
An Open Label Study, to Evaluate Safety, Tolerability, and Efficacy Study in Male and Female with Androgenetic Alopecia Treated with HMI-115 over a 24-Week Treatment Period.
- Trial name
- NCT05324293
- Testing
- HMI-115
- Where
- Australia
- Volunteers
- 16 people
- Sponsor
- Hope Medicine (Nanjing) Co., Ltd
Androgenetic Alopecia (AGA)
Phase II Study Evaluating the Efficacy and Safety of KX-826
This is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study of KX-826 in Chinese adult male patients with AGA.
- Trial name
- NCT05940506
- Testing
- KX-826-2.5 mg (0.25%)/60 mL BID, KX-826-5 mg (5%)/60 mL QD, KX-826-5 mg (5%)/60 mL BID
- Where
- 9 sites in China
- Volunteers
- 120 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Androgenic Alopecia
Androgenic Alopecia TH07 Clinical Trial
The goal of this clinical trial is to learn whether a new topical solution, TH07, can help treat androgenic alopecia in men and to learn more about its safety.
- Trial name
- MATT (NCT07435012)
- Testing
- TH07, Minoxidil 5% Topical Solution
- Where
- Canada
- Volunteers
- 420 people
- Sponsor
- Triple Hair Inc
Female Pattern Baldness
Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss
The goal of this clinical trial is to evaluate the efficacy and safety of OMA102 1 mg and OMA102 2 mg versus placebo in the treatment of female pattern hair loss.
- Trial name
- GENERA (NCT05824065)
- Testing
- OMA102
- Where
- Brazil
- Volunteers
- 504 people
- Sponsor
- EMS
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669)
Evaluate the injections of Ji Gami(TM) and Ji Gami(TM) DO, where cells are expanded ex vivo from scalp, to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451177
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 3 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Alopecia, Androgenetic
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)
The purpose of the study is to see if Clascoterone can help people with male pattern hair loss to recovery and see if the treatment is effective and safe and how well the drug is tolerated by subjects.
- Trial name
- SCALP2 (NCT05914805)
- Testing
- Clascoterone 5% solution, Vehicle solution
- Where
- 27 sites in United States, Germany and 1 more
- Volunteers
- 762 people
- Sponsor
- Cassiopea SpA
Male Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA)
Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia
The main objectives of this study are to preliminarily evaluate the effectiveness of CG2001 in treating Chinese adult male AGA participants, determine the recommended dose for Phase III clinical studies, and evaluate the safety…
- Trial name
- NCT07076706
- Testing
- minoxidil + finasteride
- Where
- 8 sites in China
- Volunteers
- 110 people
- Sponsor
- Beijing Dayspring Pharmaceutical Technology Co., Ltd
Androgenetic Alopecia, Male Pattern Baldness
Efficacy & Safety of Minoxidil SL Tablets in Men With AGA
This is a phase 3, multicentre, randomised, double-blinded, placebo-controlled study examining the safety and efficacy of 2.5 mg sublingual (SL) minoxidil tablets taken twice daily in the treatment of androgenetic alopecia (AGA)…
- Trial name
- NCT06924632
- Testing
- Minoxidil
- Where
- 3 sites in Australia
- Volunteers
- 142 people
- Sponsor
- Samson Clinical Operations Pty Ltd